Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

AIDS 2022

Written summaries from the 24th International AIDS Conference, held from July 29 – August 2, 2022.

Compliance is high with single-tablet daily PEP regimen, prevents HIV infection

Presenter: Lijun Sun, PhD, Beijing Youan Hospital, Capital Medical University Hospital, Beijing, China

A once-daily single tablet regimen of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) used as postexposure prophylaxis (PEP) taken by HIV-negative individuals after potential exposure to HIV was effective and well tolerated with a high rate of adherence and completion.

Fourth HIV-positive patient shows prolonged remission after stem cell transplant for AML

Presenter: Jana K. Dickter, MD, City of Hope Comprehensive Cancer Center, Duarte, California

HIV-1 remission has been previously reported in 2 men and 1 woman following allogeneic hematopoietic stem cell transplantation (aHCT).1-6 City of Hope Comprehensive Cancer Center researchers reported on a fourth patient (66-year-old male), diagnosed with HIV in 1988 who after developing acute myelogenous leukemia (AML) and undergoing aHCT, is in prolonged HIV remission without antiretroviral therapy (ART), according to Jana K. Dickter, MD, associate clinical professor, City of Hope Comprehensive Cancer Center, Duarte, California.

U=U must be widely known to improve quality of life of people living with HIV, improve public health

Presenter: Micheal Ighodaro, Prevention Access Campaign, United States

The U (undetectable) = U (untransmittable) campaign launched by the Prevention Access Campaign (PAC), activists, researchers, healthcare providers, and health officials improves the quality of life of people living with HIV, reduces the stigma of HIV, and accelerates progress toward 95-95-95 targets, said Micheal Ighodaro, director, Global Policy Advocacy at PAC, during a symposium designed to educate attendees about efforts to ensure that people with viral suppression have good health-related quality of life.

Subclinical atherosclerosis in HIV patients on antiretroviral therapy tied to immune signature characterized by lower levels of Th17 cells

Presenter: Tomas Raul Wiche Salinas, MD, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, Canada, and Emory University, Atlanta, Georgia

Despite suppressed HIV-1 replication under antiretroviral therapy (ART), people living with HIV (PLWH) have a higher incidence of coronary artery disease, myocardial infarction, sudden cardiac death, and peripheral artery disease compared with the general population.

More potent antiretroviral therapy regimens with broadly neutralizing antibodies are likely needed to facilitate early clearance of HIV-1 cells in infants

Presenter: Alka Khaitan, MD, Indiana University School of Medicine, Indianapolis, Indiana

Subcutaneous delivery of the monoclonal antibody VRC01 added to early antiretroviral therapy (ART), although safe and feasible, did not result in superior clearance of HIV-1-infected cells compared with ART alone in a phase I/II study of infants living with HIV-1.

High CD4 nadir implies better control of HIV provirus in patients on antiretroviral therapy

Presenter: Chuen-Yen Lau, MD, MPH, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Several cellular immune subsets correlate with HIV persistence in people living with HIV (PLWH) on long-term antiretroviral therapy (ART).

Weight gain is common after initiating or switching antiretroviral therapy

Presenter: Olivier Robineau, University of Lille, Gustave Dron Hospital, Tourcoing, France

A recent study determined that treatment-naïve as well as treatment-experienced HIV-positive individuals gain weight in the 12 months following initiation of or switch in antiretroviral therapy (ART), with an average weight gain slightly greater than the general population that varies by treatment status, third agent, backbone regimen, and preswitch backbone regimen.

Doxycycline after condomless sex prevents bacterial STIs among men on HIV PrEP or living with HIV who have sex with men and transgender women

Presenter: Annie Luetkemeyer, MD, Zuckerberg San Francisco General Hospital, University of California, San Francisco

Doxycycline taken within 72 hours of unprotected sex significantly reduces bacterial sexually transmitted infections (STI) among men who are either on HIV pre-exposure prophylaxis (PrEP) or are HIV-positive and have sex with men and transgender women, according to a randomized open-label trial.

Future of long-acting HIV prevention expected to take many forms in products and delivery

Presenter: Charles Flexner, MD, Johns Hopkins University, Baltimore; Nittaya Phanuphak, MD, PhD, Institute of HIV Research and Innovation, Bangkok, Thailand; Rachel Baggaley, MD, World Health Organization, Geneva, Switzerland

Long-acting technologies are an exciting addition to HIV treatment and prevention that may promote adherence and reduce HIV stigma. Current and future HIV prevention and long-acting treatment technologies and differentiated service delivery models were addressed in a recent satellite symposium at the 24th International AIDS (IAS) Congress.

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire